News coverage about CytomX Therapeutics (NASDAQ:CTMX) has trended somewhat positive recently, according to AlphaOne Sentiment Analysis. The research firm, a unit of Accern, identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. AlphaOne ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. CytomX Therapeutics earned a daily sentiment score of 0.15 on AlphaOne’s scale. AlphaOne also gave news headlines about the biotechnology company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an impact on the stock’s share price in the immediate future.
A number of analysts have issued reports on CTMX shares. Jefferies Group LLC reissued a “buy” rating and issued a $25.00 target price on shares of CytomX Therapeutics in a research report on Wednesday, April 26th. Zacks Investment Research lowered CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, May 29th. HC Wainwright assumed coverage on CytomX Therapeutics in a report on Monday, March 27th. They issued a “buy” rating and a $24.00 price target for the company. Instinet raised their price target on CytomX Therapeutics from $21.00 to $32.00 and gave the stock a “sell” rating in a report on Monday, March 20th. Finally, Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of CytomX Therapeutics in a report on Saturday, March 4th. Two analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $24.50.
Shares of CytomX Therapeutics (NASDAQ CTMX) traded up 4.34% during midday trading on Monday, reaching $14.19. The company’s stock had a trading volume of 267,567 shares. CytomX Therapeutics has a 12 month low of $9.10 and a 12 month high of $20.02. The company’s market cap is $521.47 million. The company’s 50-day moving average price is $14.46 and its 200-day moving average price is $13.65.
CytomX Therapeutics (NASDAQ:CTMX) last posted its earnings results on Friday, May 5th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.32. The company had revenue of $11.65 million during the quarter, compared to the consensus estimate of $2.10 million. CytomX Therapeutics had a negative net margin of 208.92% and a negative return on equity of 59.65%. On average, equities analysts anticipate that CytomX Therapeutics will post ($1.46) EPS for the current fiscal year.
In related news, major shareholder Rock Ventures Lp Third sold 1,650,000 shares of the business’s stock in a transaction on Monday, March 27th. The shares were sold at an average price of $17.39, for a total transaction of $28,693,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Sean A. Mccarthy sold 4,781 shares of the business’s stock in a transaction on Monday, May 1st. The shares were sold at an average price of $15.70, for a total transaction of $75,061.70. Following the transaction, the insider now owns 6,760 shares of the company’s stock, valued at $106,132. The disclosure for this sale can be found here. Insiders have sold 1,693,000 shares of company stock valued at $29,401,640 over the last 90 days. 8.00% of the stock is currently owned by insiders.
TRADEMARK VIOLATION WARNING: This piece was posted by BBNS and is the sole property of of BBNS. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://baseballnewssource.com/markets/cytomx-therapeutics-ctmx-receives-coverage-optimism-score-of-0-15-updated-updated/862781.html.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with our FREE daily email newsletter.